Skip to content

Study · Animal study (in vivo) · mouse · 2017

8 results

Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C

Endocrinology1 Oct 2017Cited by 7 (Europe PMC)

PMID28977588 (opens in a new tab)PMCIDPMC5659698 (opens in a new tab)DOI10.1210/en.2017-00168 (opens in a new tab)PepBankPUB-28977588
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin significantly improved glucose intolerance.

    In plain wordsIn insulin-resistant mice, hexarelin clearly improved how the body handled glucose.

    Peptide
    Hexarelin
    Outcome
    DecreaseGlucose intolerance
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin treatment significantly improved glucose and insulin intolerance and decreased plasma and liver triglycerides in MKR mice.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin significantly improved insulin intolerance.

    In plain wordsIn insulin-resistant mice, hexarelin clearly improved the response to insulin.

    Peptide
    Hexarelin
    Outcome
    DecreaseInsulin intolerance
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin treatment significantly improved glucose and insulin intolerance and decreased plasma and liver triglycerides in MKR mice.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin significantly decreased plasma triglycerides.

    In plain wordsIn insulin-resistant mice, hexarelin clearly lowered triglycerides in the blood.

    Peptide
    Hexarelin
    Outcome
    DecreasePlasma triglycerides
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin treatment significantly improved glucose and insulin intolerance and decreased plasma and liver triglycerides in MKR mice.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin significantly decreased liver triglycerides.

    In plain wordsIn insulin-resistant mice, hexarelin clearly lowered triglycerides in the liver.

    Peptide
    Hexarelin
    Outcome
    DecreaseLiver triglycerides
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Lipids · Liver
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin treatment significantly improved glucose and insulin intolerance and decreased plasma and liver triglycerides in MKR mice.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin significantly increased food intake.

    In plain wordsIn insulin-resistant mice, hexarelin clearly increased how much the mice ate.

    Peptide
    Hexarelin
    Outcome
    IncreaseFood intake
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Interestingly, although food intake of hexarelin-treated MKR mice was significantly increased, this did not change total body weight.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin did not change total body weight despite higher food intake.

    In plain wordsIn insulin-resistant mice, hexarelin did not change body weight even though the mice ate more.

    Peptide
    Hexarelin
    Outcome
    No significant changeTotal body weight
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Interestingly, although food intake of hexarelin-treated MKR mice was significantly increased, this did not change total body weight.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin decreased fat mass.

    In plain wordsIn insulin-resistant mice, hexarelin lowered body fat mass.

    Peptide
    Hexarelin
    Outcome
    DecreaseFat mass
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, hexarelin treatment corrected the abnormal body composition of MKR mice, as demonstrated by a decrease in fat mass and an increase in lean mass.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In nonobese insulin-resistant MKR mice, hexarelin increased lean mass.

    In plain wordsIn insulin-resistant mice, hexarelin raised lean body mass.

    Peptide
    Hexarelin
    Outcome
    IncreaseLean mass
    Study

    mousen: not reported in source

    Nonobese insulin-resistant MKR mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    200 μg/kg body weight twice daily · intraperitoneal · 12 daysAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, hexarelin treatment corrected the abnormal body composition of MKR mice, as demonstrated by a decrease in fat mass and an increase in lean mass.
    1 context sentence
    Summary · context
    In this study, the effects of twice daily intraperitoneal injections of hexarelin (200 μg/kg body weight) were examined in nonobese insulin-resistant MKR mice and corresponding wild-type FVB mice for 12 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.